Progress and Challenges in the Comprehensive Management of Chronic Viral Hepatitis: Key Ways to Achieve the Elimination

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2021 Jul 30

PMID 34326610

Citations 4

Authors

Fatima Higuera-De La Tijera

Alfredo Servin-Caamano

Luis Servin-Abad

Affiliations

Soon will be listed here.

Abstract

Chronic viral hepatitis is a significant health problem throughout the world, which already represents high annual mortality. By 2040, chronic viral hepatitis due to virus B and virus C and their complications cirrhosis and hepatocellular carcinoma will be more deadly than malaria, vitellogenesis-inhibiting hormone, and tuberculosis altogether. In this review, we analyze the global impact of chronic viral hepatitis with a focus on the most vulnerable groups, the goals set by the World Health Organization for the year 2030, and the key points to achieve them, such as timely access to antiviral treatment of direct-acting antiviral, which represents the key to achieving hepatitis C virus elimination. Likewise, we review the strategies to prevent transmission and achieve control of hepatitis B virus. Finally, we address the impact that the coronavirus disease 2019 pandemic has had on implementing elimination strategies and the advantages of implementing telemedicine programs.

Citing Articles

No Patient Left Behind: A Novel Paradigm to Fulfill Hepatitis C Virus Treatment for Rural Patients.

Gormley M, Moschella P, Cordero-Romero S, Wampler W, Allison M, Kitzmiller K Open Forum Infect Dis. 2024; 11(5):ofae206.

PMID: 38737428 PMC: 11088356. DOI: 10.1093/ofid/ofae206.

A care coordination program to support patients with hepatitis B virus at Kaiser Permanente Mid-Atlantic States.

Jonas M, Sheu Y, Wright K, Peyton L, Bishop R, Basra S BMC Health Serv Res. 2024; 24(1):482.

PMID: 38637807 PMC: 11027294. DOI: 10.1186/s12913-024-10907-2.

Resident macrophages of the lung and liver: The guardians of our tissues.

Kulle A, Thanabalasuriar A, Cohen T, Szydlowska M Front Immunol. 2022; 13:1029085.

PMID: 36532044 PMC: 9750759. DOI: 10.3389/fimmu.2022.1029085.

Progress on global hepatitis elimination targets.

Waheed Y World J Gastroenterol. 2022; 27(47):8199-8200.

PMID: 35068864 PMC: 8704269. DOI: 10.3748/wjg.v27.i47.8199.

References

Chang M, You S, Chen C, Liu C, Lee C, Lin S . Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009; 101(19):1348-55. DOI: 10.1093/jnci/djp288. View

Asselah T, Kowdley K, Zadeikis N, Wang S, Hassanein T, Horsmans Y . Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2017; 16(3):417-426. DOI: 10.1016/j.cgh.2017.09.027. View

Arora S, Axley P, Ahmed Z, Satapathy S, Wong R, Kuo Y . Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study. Transpl Int. 2019; 32(8):854-864. DOI: 10.1111/tri.13424. View

Popping S, El-Sayed M, Feld J, Hatzakis A, Hellard M, Lesi O . Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework. J Virus Erad. 2018; 4(3):193-195. PMC: 6038125. View

. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(5):325-336. DOI: 10.1016/S2468-1253(17)30045-6. View

Gerlich W . Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol. 2014; 204(1):39-55. DOI: 10.1007/s00430-014-0373-y. View

Makhoul M, Ayoub H, Chemaitelly H, Seedat S, Mumtaz G, Al-Omari S . Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. Vaccines (Basel). 2020; 8(4). PMC: 7712303. DOI: 10.3390/vaccines8040668. View

Young K, Liu B, Bhuket T, Wong R . Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals. J Clin Exp Hepatol. 2020; 10(6):581-589. PMC: 7719962. DOI: 10.1016/j.jceh.2020.02.003. View

Poordad F, Felizarta F, Asatryan A, Sulkowski M, Reindollar R, Landis C . Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017; 66(2):389-397. PMC: 5573922. DOI: 10.1002/hep.29081. View

10.

Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T . Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2017; 53(4):557-565. PMC: 5866824. DOI: 10.1007/s00535-017-1391-5. View

11.

Borgia S, Dearden J, Yoshida E, Shafran S, Brown A, Ben-Ari Z . Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019; 71(4):660-665. DOI: 10.1016/j.jhep.2019.05.028. View

12.

Feld J, Cypel M, Kumar D, Dahari H, Ribeiro R, Marks N . Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020; 5(7):649-657. PMC: 7391837. DOI: 10.1016/S2468-1253(20)30081-9. View

13.

Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng T, Reisch T . Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother. 2018; 62(10). PMC: 6153825. DOI: 10.1128/AAC.01249-18. View

14.

Park N, Chung Y, Lee H . Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology. 2010; 53(1):20-8. DOI: 10.1159/000252780. View

15.

Reau N, Kwo P, Rhee S, Brown Jr R, Agarwal K, Angus P . Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018; 68(4):1298-1307. PMC: 6220874. DOI: 10.1002/hep.30046. View

16.

Smit C, Boyd A, Rijnders B, van de Laar T, Leyten E, Bierman W . HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. Lancet HIV. 2020; 8(2):e96-e105. DOI: 10.1016/S2352-3018(20)30301-5. View

17.

Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V . SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. PLoS One. 2019; 14(5):e0215783. PMC: 6519817. DOI: 10.1371/journal.pone.0215783. View

18.

Feld J, Jacobson I, Hezode C, Asselah T, Ruane P, Gruener N . Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015; 373(27):2599-607. DOI: 10.1056/NEJMoa1512610. View

19.

Niederau C . Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol. 2014; 20(33):11595-617. PMC: 4155353. DOI: 10.3748/wjg.v20.i33.11595. View

20.

Choudhary N, Saraf N, Saigal S, Rastogi A, Bhangui P, Thiagrajan S . Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era. Indian J Gastroenterol. 2020; 39(6):539-543. DOI: 10.1007/s12664-020-01105-z. View